238,326 Shares in Lantheus Holdings, Inc. $LNTH Acquired by Nitorum Capital L.P.

Key Points

• Nitorum Capital L.P. acquired 238,326 shares of Lantheus Holdings, Inc. (LNTH) in the first quarter, valued at approximately $23.3 million, making it 13th in their portfolio holdings.
• Multiple institutional investors, including Assenagon Asset Management and GAMMA Investing, significantly increased their stakes in Lantheus, indicating strong interest in the company.
• Lantheus recently reported earnings per share of $1.57, missing analyst estimates of $1.65, with a revenue of $378.05 million for the quarter, down 4.1% year-over-year.

Nitorum Capital L.P. purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 238,326 shares of the medical equipment provider's stock, valued at approximately $23,261,000. Lantheus makes up 3.3% of Nitorum Capital L.P.'s portfolio, making the stock its 13th largest holding. Nitorum Capital L.P. owned 0.35% of Lantheus at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Lantheus by 3.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,084 shares of the medical equipment provider's stock valued at $1,162,000 after acquiring an additional 400 shares in the last quarter. State of Alaska Department of Revenue boosted its holdings in shares of Lantheus by 2.7% during the 1st quarter. State of Alaska Department of Revenue now owns 8,142 shares of the medical equipment provider's stock valued at $794,000 after buying an additional 215 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Lantheus by 12,517.1% during the 1st quarter. GAMMA Investing LLC now owns 128,442 shares of the medical equipment provider's stock valued at $12,536,000 after buying an additional 127,424 shares in the last quarter. Cetera Investment Advisers boosted its holdings in shares of Lantheus by 21.4% during the 1st quarter. Cetera Investment Advisers now owns 28,362 shares of the medical equipment provider's stock valued at $2,768,000 after buying an additional 5,004 shares in the last quarter. Finally, Cerity Partners LLC boosted its holdings in shares of Lantheus by 12.7% during the 1st quarter. Cerity Partners LLC now owns 11,709 shares of the medical equipment provider's stock valued at $1,143,000 after buying an additional 1,323 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Insider Transactions at Lantheus

In other news, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. This represents a 49.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the completion of the transaction, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. This trade represents a 49.18% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 6,812,000 shares of company stock valued at $382,427,380. 2.00% of the stock is owned by insiders.

Lantheus Stock Up 1.7%

Lantheus stock traded up $0.93 during mid-day trading on Friday, reaching $54.75. The stock had a trading volume of 889,412 shares, compared to its average volume of 1,691,628. The company has a market capitalization of $3.72 billion, a price-to-earnings ratio of 14.56 and a beta of 0.15. The company has a 50-day moving average price of $66.59 and a two-hundred day moving average price of $82.27. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $118.21. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.29 and a quick ratio of 4.07.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm had revenue of $378.05 million during the quarter, compared to the consensus estimate of $389.69 million. During the same quarter in the previous year, the firm earned $1.80 EPS. The business's revenue for the quarter was down 4.1% on a year-over-year basis. On average, analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on LNTH. Mizuho dropped their target price on shares of Lantheus from $120.00 to $70.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th. JMP Securities dropped their target price on shares of Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. B. Riley dropped their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating on the stock in a report on Monday, June 23rd. William Blair restated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. Finally, Truist Financial set a $63.00 target price on shares of Lantheus and gave the company a "hold" rating in a report on Monday, August 11th. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Lantheus currently has a consensus rating of "Moderate Buy" and an average price target of $91.60.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.